NTZ Lab Ltd., Krasno selo 198, Sofia, 1618, Bulgaria.
Department of Chemistry, Bielefeld University, Universitätsstr. 25, 33615, Bielefeld, Germany.
Eur J Med Chem. 2019 Oct 1;179:404-422. doi: 10.1016/j.ejmech.2019.06.041. Epub 2019 Jun 19.
A comprehensive study was performed for the first time to compare two structurally related substance classes, namely indazole-5-carboxamides (11-16) and (indazole-5-yl)methanimines (17-22). Both chemical entities are potent, selective and reversible MAO-B inhibitors and, therefore, may serve as promising lead structures for the development of drug candidates against Parkinson's disease (PD) and other neurological disorders. Compounds 15 (K = 170 pM, SI = 25907) and 17 (K = 270 pM, SI = 16340) were the most potent and selective MAO-B inhibitors in both series. To investigate the multi-target inhibitory activity, all compounds were further screened for their potency against human AChE and BuChE enzymes. Compound 15 was found to be the most potent and selective AChE inhibitor in all series (hAChE IC = 78.3 ± 1.7 μM). Moreover, compounds 11 and 17 showed no risk of drug-induced hepatotoxicity and a wider safety window, as determined in preliminary cytotoxicity screening. Molecular modeling studies into the human MAO-B enzyme-binding site supported by a HYDE analysis suggested that the imine linker similarly contributes to the total binding energy in methanimines 17-22 as the amide spacer in their carboxamide analogs 11-16. Amplified photophysical evaluation of compounds 17 and 20, including single X-ray analysis, photochemical experiments, and quantum-chemical calculations, provided insights into their more favourable isomeric forms and structural features, which contribute to their biologically active form and promising drug-like properties.
首次进行了一项全面的研究,比较了两种结构相关的物质类别,即吲唑-5-甲酰胺(11-16)和(吲唑-5-基)亚甲胺(17-22)。这两种化学实体都是有效的、选择性的和可逆的 MAO-B 抑制剂,因此可能成为开发治疗帕金森病(PD)和其他神经障碍候选药物的有前途的先导结构。化合物 15(K=170 pM,SI=25907)和 17(K=270 pM,SI=16340)是这两个系列中最有效和选择性的 MAO-B 抑制剂。为了研究多靶点抑制活性,进一步筛选了所有化合物对人乙酰胆碱酯酶和丁酰胆碱酯酶的抑制作用。在所有系列中,化合物 15 被发现是最有效和选择性的 AChE 抑制剂(hAChE IC=78.3±1.7μM)。此外,在初步的细胞毒性筛选中,化合物 11 和 17 被发现没有药物引起肝毒性的风险,并且安全窗更宽。通过 HYDE 分析支持的人 MAO-B 酶结合位点的分子建模研究表明,亚胺键同样有助于亚甲胺 17-22 中的总结合能,就像酰胺间隔物在它们的羧酰胺类似物 11-16 中一样。对化合物 17 和 20 的放大光物理评估,包括单晶 X 射线分析、光化学实验和量子化学计算,提供了对它们更有利的异构体形式和结构特征的深入了解,这些特征有助于它们的生物活性形式和有前途的类药性。